Immunodiagnostic Systems Holdings
Market Cap
UK£66.2m
Last Updated
2020/01/23 20:34 UTC
Data Sources
Company Financials
Executive Summary
Immunodiagnostic Systems Holdings PLC develops, manufactures, and sells in-vitro diagnostic tests to the clinical laboratory market in the United Kingdom, the United States, Germany, France, and internationally.
Rewards
Risk Analysis
Snowflake Analysis
Flawless balance sheet with acceptable track record.
Similar Companies
Share Price & News
How has Immunodiagnostic Systems Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: IDH's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-13.2%
IDH
-0.3%
GB Medical Equipment
-0.5%
GB Market
1 Year Return
26.0%
IDH
32.8%
GB Medical Equipment
12.4%
GB Market
Return vs Industry: IDH underperformed the UK Medical Equipment industry which returned 31.5% over the past year.
Return vs Market: IDH exceeded the UK Market which returned 12.7% over the past year.
Shareholder returns
| IDH | Industry | Market | |
|---|---|---|---|
| 7 Day | -13.2% | -0.3% | -0.5% |
| 30 Day | -15.8% | 2.7% | 0.2% |
| 90 Day | -14.8% | 12.7% | 6.0% |
| 1 Year | 26.5%26.0% | 35.2%32.8% | 18.3%12.4% |
| 3 Year | -3.9%-6.1% | 45.0%37.5% | 22.6%6.9% |
| 5 Year | -27.3%-30.3% | 72.7%58.1% | 40.9%8.3% |
Price Volatility Vs. Market
How volatile is Immunodiagnostic Systems Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
If You Had Bought Immunodiagnostic Systems Holdings (LON:IDH) Shares A Year Ago You'd Have Made 50%1 month ago | Simply Wall St
Immunodiagnostic Systems Holdings PLC’s (LON:IDH) Investment Returns Are Lagging Its Industry3 months ago | Simply Wall St
Should You Be Worried About Immunodiagnostic Systems Holdings PLC's (LON:IDH) 1.4% Return On Equity?Valuation
Is Immunodiagnostic Systems Holdings undervalued compared to its fair value and its price relative to the market?
59.27x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: IDH (£2.73) is trading above our estimate of fair value (£0.23)
Significantly Below Fair Value: IDH is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: IDH is poor value based on its PE Ratio (70.3x) compared to the Medical Equipment industry average (34.4x).
PE vs Market: IDH is poor value based on its PE Ratio (70.3x) compared to the UK market (18.5x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IDH's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IDH is good value based on its PB Ratio (1.4x) compared to the GB Medical Equipment industry average (3.4x).
Next Steps
Future Growth
How is Immunodiagnostic Systems Holdings forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
12.5%
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Immunodiagnostic Systems Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Next Steps
- Examine Immunodiagnostic Systems Holdings's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Immunodiagnostic Systems Holdings competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Healthcare industry.
Past Performance
How has Immunodiagnostic Systems Holdings performed over the past 5 years?
20.5%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IDH has high quality earnings.
Growing Profit Margin: IDH became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: IDH has become profitable over the past 5 years, growing earnings by 20.5% per year.
Accelerating Growth: IDH has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: IDH has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-4.5%).
Return on Equity
High ROE: IDH's Return on Equity (2%) is considered low.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Immunodiagnostic Systems Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: IDH's short term assets (£48.1M) exceed its short term liabilities (£7.1M).
Long Term Liabilities: IDH's short term assets (£48.1M) exceed its long term liabilities (£4.3M).
Debt to Equity History and Analysis
Debt Level: IDH is debt free.
Reducing Debt: IDH has no debt compared to 5 years ago when its debt to equity ratio was 2.2%.
Debt Coverage: IDH has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: IDH has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Inventory Level: IDH has a high level of physical assets or inventory.
Debt Coverage by Assets: IDH's debt is covered by short term assets (assets are 1.0839488763137E+17x debt).
Next Steps
Dividend
What is Immunodiagnostic Systems Holdings's current dividend yield, its reliability and sustainability?
0.30%
Current Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: IDH's dividend (0.26%) isn’t notable compared to the bottom 25% of dividend payers in the UK market (1.83%).
High Dividend: IDH's dividend (0.26%) is low compared to the top 25% of dividend payers in the UK market (4.95%).
Stability and Growth of Payments
Stable Dividend: IDH is not paying a notable dividend for the UK market, therefore no need to check if payments are stable.
Growing Dividend: IDH is not paying a notable dividend for the UK market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: IDH is not paying a notable dividend for the UK market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IDH's dividend in 3 years as they are not forecast to pay a notable one for the UK market.
Next Steps
Management
What is the CEO of Immunodiagnostic Systems Holdings's salary, the management and board of directors tenure and is there insider trading?
4.0yrs
Average management tenure
CEO
Jaap Stuut (49yo)
2.2yrs
Tenure
UK£233,000
Compensation
Mr. Jaap Stuut has been the Chief Executive Officer of Immunodiagnostic Systems Holdings PLC since October 31, 2017. Mr. Stuut has been with the Immunodiagnostic Systems Holdings PLC since 2013 and was pre ...
CEO Compensation Analysis
Compensation vs Market: Jaap's total compensation ($USD302.59K) is about average for companies of similar size in the UK market ($USD326.78K).
Compensation vs Earnings: Jaap's compensation has been consistent with company performance over the past year.
Management Age and Tenure
4.0yrs
Average Tenure
49yo
Average Age
Experienced Management: IDH's management team is considered experienced (4 years average tenure).
Board Age and Tenure
4.2yrs
Average Tenure
53yo
Average Age
Experienced Board: IDH's board of directors are considered experienced (4.2 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Management Team
Ed Coombes (48yo)
Head Of Business Development - Instrumentation
Rudolf Schemer (58yo)
CEO of GeschTMaftsfuhrer at IDS GmbH Frankfurt & Country Manager of Germany Region
- Tenure: 12.8yrs
Nicola Mitton
Group HR Director
Paul Martin
Group Finance Director
- Tenure: 4yrs
- Compensation: UK£229.00k
Jaap Stuut (49yo)
CEO & Director
- Tenure: 2.2yrs
- Compensation: UK£233.00k
Board Members
Burkhard Wittek (65yo)
Non-Executive Chairman
- Tenure: 5yrs
- Compensation: UK£60.00k
Peter Kaspar
Non-Executive Director
- Tenure: 4.2yrs
- Compensation: UK£30.00k
Peter Williamson (53yo)
Non-Executive Director
- Tenure: 4.6yrs
- Compensation: UK£30.00k
Paul Martin
Group Finance Director
- Tenure: 4yrs
- Compensation: UK£229.00k
Jaap Stuut (49yo)
CEO & Director
- Tenure: 2.2yrs
- Compensation: UK£233.00k
Company Information
Immunodiagnostic Systems Holdings PLC's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Immunodiagnostic Systems Holdings PLC
- Ticker: IDH
- Exchange: AIM
- Founded: 1977
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: UK£66.203m
- Shares outstanding: 28.78m
- Website: https://www.idsplc.com
Number of Employees
Location
- Immunodiagnostic Systems Holdings PLC
- Boldon Business Park
- 10 Didcot Way
- Boldon
- Tyne and Wear
- NE35 9PD
- United Kingdom
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| IDH | AIM (London Stock Exchange AIM Market) | Yes | Ordinary Shares | GB | GBP | Dec 2004 |
| LWX | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | Dec 2004 |
Biography
Immunodiagnostic Systems Holdings PLC develops, manufactures, and sells in-vitro diagnostic tests to the clinical laboratory market in the United Kingdom, the United States, Germany, France, and internationally. It develops, manufactures, and markets immunoassays and automated immunoanalyser technologies to provide diagnostic outcomes for patients. It offers IDS-iSYS multi-discipline automated systems, which is based on chemiluminescence and absorbency technology is used for immunoassay testing. The company provides its products and services for diagnosis of bone metabolism, calcium metabolism, hypertension, chronic kidney disease mineral bone disorder, growth, fertility, autoimmunity, infectious disease, sarcoidosis, and allergy. Immunodiagnostic Systems Holdings PLC was founded in 1977 and is headquartered in Boldon, the United Kingdom.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/01/23 20:34 |
| End of Day Share Price | 2020/01/23 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2019/03/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.